Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma

被引:1
|
作者
Zhu, Wei-Hang [1 ,2 ]
Chen, Jie [1 ,2 ]
Huang, Run-Kai [1 ,2 ]
Zhang, Yuan [3 ]
Huang, Ze-Xuan [2 ,4 ]
Pang, Xiu-Qing [2 ,4 ]
Hu, Bo [5 ]
Yang, Yang [6 ,7 ,8 ]
Li, Xing [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Obstet, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Lab Med, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 3, Liver Transplantat Ctr, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Liver Dis Res, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
来源
THERANOSTICS | 2023年 / 13卷 / 13期
基金
中国国家自然科学基金;
关键词
Portal vein tumor thrombus; Coagulation; CD45(+) EPC; Hepatocellular carcinoma; Vascular endothelial cells; SUPPRESSOR-CELLS; FIBRINOGEN;
D O I
10.7150/thno.82907
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Hepatocellular carcinoma (HCC) is primarily characterized by a high incidence of vascular invasion. However, the specific mechanism underlying portal vein tumor thrombus (PVTT) in HCC remains unclear. As a consequence of myeloid cell developmental arrest, CD71(+) erythroid progenitor cells (EPCs) and myeloid-derived suppressor cells play important roles in HCC; however, their roles in PVTT remain unclear. Methods: The role of CD71(+) EPCs in the HCC tumor microenvironment (TME) was evaluated via morphological, RNA- sequencing, enzyme-linked immunosorbent assay, and flow cytometric analyses. Co-culture techniques were employed to assess the CD45(+) EPCs and their vascular compromising effect. Additionally, the PVTT-promoting function of CD45(+) EPCs was explored in vivo in a murine model. Results: The CD45(+) EPCs in HCC tissues exhibited increased myeloid cell features, including morphology, surface markers, transforming growth factor ( TGF)-beta generation, and gene expression, compared with those in circulation. Hence, a large proportion of CD45(+)EPCs, particularly those in TMEs, comprise erythroid-transdifferentiated myeloid cells (EDMCs). Additionally, the expression of C-C chemokine receptor type 2 (CCR2) mRNA was upregulated in CD45(+)EPCs within the TME. Tumor macrophages from HCC tissues induced substantial migration of CD45(+)EPCs in a dose-dependent manner. Meanwhile, results from immunofluorescence analyses revealed that these two cell types are positively associated in the TME and circulation. That is, EDMCs are chemoattracted by HCC macrophages mainly via CCR2 from CD45(+) EPCs in the circulation. Additionally, the expressions of FX, FVII, FGB, C4b, CFB, and CFH were elevated in CD45(+)EPCs within the TME compared with those in the spleen. The CD45(+)EPCs from the HCC TME promoted vessel endothelial cell migration and compromised tube formation through TGF-beta and FGB, respectively. Additionally, CD45(+)EPCs from the TME induced HCC cell migration. HCC macrophage-induced CD45(+)EPCs to exhibit higher levels of FX, FVII, FGB, and TGF-beta. Meanwhile, upregulation of CCAAT/enhancer binding protein beta expression induced FGB and TGF-beta generation in CD45(+)EPCs in the TME. WTAP, a major RNA m(6)A writer, stabilized FX and FVII mRNA and enhanced their nuclear export in CD45(+)EPCs from the TME. CD45(+)EPCs from the TME were positively associated with PVTT and poor prognosis. Splenectomy reduced the level of CD45(+)EPCs in the circulation and TME, as well as the incidence of microvascular invasion. The incidence of microvascular invasion increased following the transfer of HCC tissue CD45(+)EPCs to splenectomized HCC-bearing mice. Conclusions: The CD45(+)EPCs enriched in the HCC microenvironment are EDMCs, which are induced by HCC macrophages to migrate from the circulation to the TME. Subsequently, EDMCs promote PVTT by compromising the blood vessel endothelium, aggravating coagulation, and promoting HCC cell migration.
引用
收藏
页码:4316 / 4332
页数:17
相关论文
共 50 条
  • [1] Hepatocellular carcinoma with portal vein tumor thrombus
    Sniderman, KW
    RADIOLOGY, 1998, 207 (02) : 552 - 553
  • [2] Hepatocellular carcinoma with portal vein tumor thrombus - Response
    Furuse, J
    Iwasaki, M
    Yoshino, M
    Konishi, M
    Kawano, N
    Kinoshita, T
    Ryu, M
    Satake, M
    Moriyama, N
    RADIOLOGY, 1998, 207 (02) : 553 - 553
  • [3] Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus
    Toshiya Kamiyama
    Tatsuhiko Kakisaka
    Tatsuya Orimo
    Kenji Wakayama
    World Journal of Hepatology, 2017, (36) : 1296 - 1304
  • [4] The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
    Luo, Fangzhou
    Li, Mengxia
    Ding, Jun
    Zheng, Shusen
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma
    JuXian Sun
    Jie Shi
    Nan Li
    WeiXing Guo
    MengChao Wu
    WanYee Lau
    ShuQun Cheng
    Cancer Biology & Medicine, 2016, 13 (04) : 452 - 458
  • [6] Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
    Shi, Jie
    Lai, Eric C. H.
    Li, Nan
    Guo, Wei-Xing
    Xue, Jie
    Lau, Wan Yee
    Wu, Meng-Chao
    Cheng, Shu-Qun
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (08) : 2073 - 2080
  • [7] Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus
    Minagawa, Masami
    Makuuchi, Masatoshi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (47) : 7561 - 7567
  • [8] Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus
    Masami Minagawa
    Masatoshi Makuuchi
    World Journal of Gastroenterology, 2006, (47) : 7561 - 7567
  • [9] Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma
    Sun, Ju-Xian
    Shi, Jie
    Li, Nan
    Guo, Wei-Xing
    Wu, Meng-Chao
    Lau, Wan-Yee
    Cheng, Shu-Qun
    CANCER BIOLOGY & MEDICINE, 2016, 13 (04) : 452 - 458
  • [10] The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus
    Qiu, Guoteng
    Xie, Kunlin
    Jin, Zhaoxing
    Jiang, Chuang
    Liu, Hu
    Wan, Haifeng
    Huang, Jiwei
    BIOSCIENCE TRENDS, 2021, 15 (03) : 148 - 154